Introduction
Immunoprecipitation (IP) has evolved far beyond its origins as a manual protein capture technique. What began in the 1980s as a qualitative method for detecting antigen-antibody interactions has transformed into a quantitative, multi-platform systems biology tool that integrates with mass spectrometry, proximity labeling, next-generation sequencing, and spatial omics. The central challenge has remained constant—selective enrichment of a protein of interest from a complex biological mixture—but the experimental framework for addressing this challenge has expanded dramatically. Researchers now choose not only between antibodies and bead chemistries, but between fundamentally different interaction capture strategies: classical co-IP for stable complexes, chemical crosslinking for transient interactions, proximity labeling for spatial neighborhoods, and CUT&Tag for chromatin associations. Each strategy carries distinct assumptions about the nature of the interaction being measured and imposes different requirements for controls, quantification, and data interpretation. This guide provides an evidence-based framework for selecting, optimizing, and validating IP-based approaches in the context of 2024-2026 methodological advances, with emphasis on experimental design decisions that determine data quality.
Antibody Selection and Validation for IP-Grade Applications
The antibody is the single most determinant factor in IP experiment quality. Unlike antibodies used for Western blotting or immunofluorescence, which can tolerate moderate cross-reactivity because target identification relies on molecular weight or spatial resolution, IP antibodies must capture their target from a complex mixture under conditions that preserve native protein conformation, and the captured material is often analyzed by methods that cannot distinguish the target from co-purifying contaminants.
Critical Parameters Beyond Affinity
Commercial antibody datasheets typically report affinity (KD) and specificity by Western blot, but these metrics are insufficient predictors of IP performance. Three parameters that correlate more strongly with IP success are epitope accessibility under native conditions, off-target capture rate, and batch-to-batch consistency. Epitope accessibility is particularly underappreciated: an antibody raised against a linear peptide epitope may function excellently in denaturing applications but fail in native IP because the epitope is buried within the folded protein structure. Antibodies raised against recombinant full-length protein or properly folded extracellular domains are more likely to recognize the native conformation required for IP. The off-target capture rate can be quantitatively assessed by comparing IP-MS results from wild-type samples versus knockout (KO) control samples: true interactors should be enriched only in the wild-type IP, while proteins that appear in both wild-type and KO IPs represent nonspecific background. A 2024 study evaluating 120 commercial IP antibodies found that approximately 35% showed acceptable specificity by this KO-based criterion, underscoring the need for rigorous validation before committing to large-scale experiments. Recombinant antibodies, produced from fully sequenced variable regions, offer a solution to batch-to-batch inconsistency that has become a growing concern for traditional monoclonal and polyclonal antibodies. A 2025 review of AI-driven antibody design highlighted that computational methods, including those from the David Baker laboratory published in Nature Biotechnology in 2026, can now generate recombinant antibodies with designed epitope specificity and optimized biophysical properties for IP applications.
Cross-Validation Strategies
A minimum validation framework for an IP-grade antibody should include three tests. First, Western blot confirmation that the antibody recognizes a band at the correct molecular weight in the input lysate and that this band is absent or diminished in a KO or knockdown control. Second, IP followed by Western blot (IP-WB) demonstrating that the antibody captures the target protein from the lysate and that the captured material runs at the correct molecular weight. Third, IP-MS from both wild-type and KO samples to establish the target-to-background signal ratio and to generate an empirical list of proteins that consistently co-purify with the target. The CRAPome database provides a reference compendium of common IP-MS contaminants across hundreds of experiments; any protein appearing in the CRAPome with a high frequency should be viewed with skepticism unless it is consistently enriched above the KO control. For antibodies that fail these validation tests, alternative strategies include epitope tagging (FLAG, HA, Myc, or Strep-tag II) combined with a high-quality anti-tag antibody, which bypasses the need for a protein-specific IP antibody and allows standardized IP conditions across multiple targets. IP-MS protein interactomics services routinely incorporate these validation steps as part of their quality control pipeline.
Figure 1: IP-Grade Antibody Validation Decision Flowchart
Sequential validation gates from Western blot confirmation through KO-based specificity assessment to CRAPome background filtering.
Systematic Optimization of IP Conditions
Conventional IP optimization advice—"adjust buffer pH, salt concentration, and detergent type"—provides no guidance on how these parameters interact or what combinations are most likely to succeed for a given target. A systematic approach that simultaneously evaluates multiple variables dramatically outperforms one-factor-at-a-time optimization.
Multiparameter Optimization Platforms
A 2024 study published in Nature Communications introduced a 384-well plate-based format that screens 32 IP condition combinations in parallel, measuring target capture yield and nonspecific binding by automated Western blot or MS readout. The format tests four variables simultaneously: lysis buffer composition (RIPA vs Triton X-100 vs NP-40 vs digitonin), salt concentration (150 mM vs 300 mM vs 500 mM NaCl), detergent concentration (0.1% vs 0.5% vs 1% vs 2%), and bead type (protein A vs protein G vs magnetic vs agarose). In a test set of 24 antibodies, the optimal condition identified by the multiparameter screen improved target recovery by an average of 3.2-fold compared to the manufacturer-recommended condition, while reducing IgG-heavy-chain contamination by 40%. Machine learning models trained on the resulting dataset were able to predict optimal buffer conditions for unseen antibodies with 72% accuracy, suggesting that data-driven optimization may eventually replace empirical screening for routine IP targets.
Wash Strategy and Stringency Control
The washing phase is where the specificity-versus-yield trade-off is most acute. Insufficient washing leaves background proteins bound to the beads, while overly stringent washing disrupts genuine interactions. The most effective approach is gradient washing: a series of three to five washes with progressively increasing stringency (e.g., 150 mM NaCl to 500 mM NaCl, or 0.1% Triton to 0.5% Triton), with each wash fraction collected and analyzed separately. This reveals which interacting proteins are stably bound (resistant to high-stringency washes) versus weakly associated (removed by early washes), providing a built-in interaction stability metric that is lost in single-condition washes. For crosslinked IP (see below), denaturing washes containing 0.1% SDS or 1 M urea can be applied without disrupting the crosslinked interaction, effectively removing non-covalently associated contaminants that survive native washing conditions.
Controls for Quantitative Comparison
The minimum control set for an interpretable IP experiment includes: (1) a target-specific IP from a KO or knockdown lysate, to distinguish true interactors from proteins that bind the antibody or beads independently of the target; (2) a nonspecific IgG or isotype control IP from wild-type lysate at the same antibody concentration, to identify proteins that bind the immunoglobulin itself; (3) a "beads-only" control (no antibody), to identify proteins that bind the solid support directly. Quantitative comparison between these controls and the target IP, using spectral counts or intensity-based MS quantification, allows calculation of enrichment ratios that distinguish specific from nonspecific associations. Co-immunoprecipitation services typically implement this three-control framework as a minimum standard for data reliability.
Figure 2: Multiparameter IP Condition Optimization Heat Map
384-well plate-based screen showing target capture yield across 32 buffer/bead/detergent combinations, with optimal condition highlighted.
Crosslinking Strategies for Transient and Weak Interactions
Classical IP captures only interactions that survive cell lysis, antibody incubation, and multiple washing steps—a selection pressure that systematically biases against transient, low-affinity, or detergent-sensitive interactions. Crosslinking before IP covalently stabilizes these labile interactions before lysis, enabling their detection.
Chemical Crosslinker Selection
The choice of crosslinker determines which types of interactions are captured. DSP (dithiobis[succinimidyl propionate]) is a membrane-permeable, thiol-cleavable crosslinker with a 12-angstrom spacer arm, ideal for capturing intracellular protein complexes in live cells before lysis. BS3 (bis[sulfosuccinimidyl] suberate) is membrane-impermeable and water-soluble, suitable for crosslinking cell surface or extracellular protein complexes. DSG (disuccinimidyl glutarate) provides a shorter 7.7-angstrom arm for crosslinking within tight protein interfaces. Formaldehyde is the least specific but most penetrative crosslinker, creating both protein-protein and protein-DNA crosslinks; it is the standard for chromatin IP (ChIP) and is increasingly used for in vivo XL-MS. Each crosslinker requires optimization of concentration (typically 0.5-2 mM for DSP/BS3/DSG, 0.1-1% for formaldehyde), temperature (4 deg C to reduce metabolic activity during crosslinking), and duration (10-30 minutes for chemical crosslinkers, 5-15 minutes for formaldehyde). Over-crosslinking creates excessive inter-molecular bridges that reduce protein extractability and increase nonspecific aggregation; the optimal condition is the minimum concentration and time that stabilizes the interaction of interest without substantially reducing protein recovery from the lysate.
In Vivo Crosslinking Mass Spectrometry
A major advance in 2024 was the demonstration that cell fixation with formaldehyde or paraformaldehyde before lysis dramatically improves the reproducibility and depth of in vivo XL-MS. A Nature Communications study showed that fixation increases the number of identified crosslinked peptide pairs by 3-fold compared to crosslinking in lysate, and the fixed-cell protocol identified 4,700 unique crosslinked residue pairs from HEK293 cells—the largest in vivo XL-MS dataset reported to date. The key innovation was the use of a brief (10-minute) formaldehyde fixation step before lysis, followed by crosslinking with DSSO (disuccinimidyl sulfoxide) in the lysate, combining the advantages of in vivo stabilization with the higher efficiency of in vitro crosslinking. For RNA-binding protein identification, UV crosslinking at 254 nm followed by IP of the target RBP (RBP-IP) and RNA sequencing of the bound fragments has been the gold standard since the development of CLIP-seq methods. A 2025 Nucleic Acids Research study extended this approach by combining UV crosslinking with chemical crosslinking (DSP), capturing both direct RNA-protein contacts and indirect protein-protein interactions within RBP complexes simultaneously. Crosslinking protein interaction analysis services now routinely offer both chemical and UV crosslinking options depending on the interaction type under investigation.
Figure 3: Crosslinking Strategy Selection Matrix
Technical comparison of DSP, BS3, DSG, formaldehyde, and UV crosslinking across membrane permeability, arm length, reversibility, and application suitability.
Proximity Labeling: From BioID to Split-TurboID
Proximity labeling (PL) represents a conceptual departure from classical IP. Instead of capturing the protein of interest and its bound partners, PL enzymatically tags all proteins within a defined spatial radius of the target in living cells, and the tags are subsequently purified by streptavidin capture. This approach detects both direct binding partners and proteins that are physically close without direct contact, providing a spatial neighborhood map rather than a binary interaction list.
The PL Toolbox: Speed and Specificity Trade-Offs
The first widely adopted PL enzyme, BioID, is a promiscuous biotin ligase mutant (R118G) derived from E. coli BirA. BioID biotinylates proximal proteins within a radius of approximately 10 nm over 12-24 hours of labeling. The long labeling time is a limitation for studying dynamic processes, but it ensures comprehensive coverage of low-abundance targets. TurboID, engineered by directed evolution of BioID, accelerates labeling to 10 minutes while maintaining comparable labeling radius. This speed enables pulse-chase experiments to track protein complex dynamics and reduces the risk of labeling proteins that move into the proximity zone during the extended BioID labeling period. A 2024 study applied TurboID to identify virus-host protein interactions during SARS-CoV-2 infection, capturing known interactors and 47 previously unreported host proteins that associated with viral proteins within minutes of infection.
The most recent innovation is split-proximity labeling, in which the labeling enzyme is divided into two inactive fragments, each fused to a different protein. Functional enzyme activity is reconstituted only when the two fusion proteins are brought into proximity, either by direct binding or by localization to the same cellular compartment. A 2026 Trends in Biochemical Sciences review highlighted split-TurboID and split-BioID as transformative tools for mapping protein interaction interfaces with spatial precision that standard PL cannot achieve. The split-enzyme approach reports not just that two proteins are in the same neighborhood, but that their relative orientation allows enzyme complementation—a more stringent proximity filter. Split-TurboID has been applied to map the interaction interface of the nuclear pore complex, identifying which nucleoporin pairs are within sufficient proximity for enzyme complementation and which are not, information that aligns closely with cryo-EM structural data.
Spatial Resolution and the Risk of False Positives
All PL methods share a fundamental limitation: they label proximity, not binding. A 2025 Nature Chemical Biology study used spatially barcoded PL probes to measure the effective labeling radii of TurboID and APEX2 in situ. The results showed that TurboID has an effective labeling radius of approximately 10 nm, while APEX2 labels within approximately 20 nm. These distances are larger than typical protein-protein interaction interfaces (3-5 nm), meaning that PL inevitably labels proteins that are proximal but not interacting. The study recommended three complementary strategies to distinguish genuine interactors from proximity artifacts: (1) comparative PL using a cytosolic or nuclear-localized free enzyme control to identify proteins that are labeled simply because they are abundant in the same subcellular compartment; (2) quantitative time-resolved PL to distinguish rapid labeling of direct interactors from slower labeling of bystanders; and (3) orthogonal validation of a subset of candidates by classical co-IP or crosslinking. BioID-MS services and TurboID proximity labeling services typically incorporate these control strategies as standard components of the experimental design consultation.
Figure 4: Proximity Labeling Technology Evolution Timeline
Evolutionary progression from BioID (2012) through TurboID (2018) to split-proximity labeling (2024-2026), annotated with labeling speed, spatial resolution, and key application milestones.
CUT&Tag and Next-Generation Epigenetic Profiling
Chromatin immunoprecipitation (ChIP) has been the standard method for mapping protein-DNA interactions and histone modifications for two decades, but it suffers from high input requirements, crosslinking artifacts, and limited resolution. Cleavage Under Targets and Tagmentation (CUT&Tag) has emerged since 2019 as a superior alternative that addresses these limitations by using a protein A-Tn5 transposase fusion to tagment DNA directly at the antibody-targeted locus.
Why CUT&Tag Supersedes ChIP for Most Applications
The fundamental innovation of CUT&Tag is that the Tn5 transposase is delivered to the target site by the primary antibody through a protein A linker, and the transposase simultaneously fragments and tags the neighboring DNA with sequencing adapters in a single step. This eliminates the need for sonication, end repair, A-tailing, and adapter ligation that constitute the most variable and sample-consuming steps of the ChIP protocol. The practical consequences are substantial: CUT&Tag requires 10,000-fold less input material than ChIP (100-1,000 cells vs 1-10 million cells), produces lower background due to the absence of crosslinking (crosslinking in ChIP captures indirect DNA associations that inflate false-positive rates), and achieves higher resolution because Tn5 cuts within accessible chromatin immediately adjacent to the antibody binding site. A 2024 review of CUT&Tag derivatives cataloged over 15 methodological variants optimized for different applications, including multi-factor CUT&Tag for simultaneous profiling of two histone marks, ultra-low-input CUT&Tag for 100-cell inputs, and high-throughput CUT&Tag in 96-well plate format for drug screening applications.
Single-Cell and Spatially Resolved CUT&Tag
The most significant recent advances extend CUT&Tag to single-cell and spatial resolution. scNanoSeq-CUT&Tag, published in Nature Methods in 2024, combines droplet-based single-cell barcoding with long-read sequencing to profile histone modifications and chromatin accessibility simultaneously in individual cells. The method achieves detection of 3,000-8,000 unique fragments per cell, comparable to scChIP-seq but with substantially simpler library preparation. A 2026 preprint described Super-CUT&Tag, which adapts the CUT&Tag chemistry for use on intact tissue sections by permeabilizing the tissue and delivering the antibody-Tn5 complex through the permeabilized membrane, generating spatially resolved epigenomic maps at 50-micrometer resolution. These developments are transforming CUT&Tag from a low-throughput biochemical assay into a scalable platform for epigenomic discovery across tissues and cell types.
Experimental Design Considerations for CUT&Tag
Three parameters critically affect CUT&Tag data quality. First, concanavalin A (ConA) magnetic bead binding efficiency determines the fraction of cells or nuclei that are retained through the wash steps; binding efficiency below 80% introduces sampling bias and reduces the effective input material. Second, the pAG-Tn5 fusion protein shows batch-to-batch variability in transposition activity that directly affects tagmentation efficiency and fragment size distribution. Each new batch of pAG-Tn5 should be titrated (typically 0.5-2 ng per reaction) and tested on a standard positive control antibody (e.g., anti-H3K27me3 or anti-RNA Polymerase II) before use on experimental samples. Third, endogenous DNA fragments from dead or damaged cells contribute disproportionately to background reads. A viability threshold of at least 85% before ConA binding, assessed by trypan blue exclusion or automated cell counting, is recommended to maintain signal-to-background ratios above 10:1. Chromatin profiling services that incorporate CUT&Tag now include these QC parameters as standard operating procedures.
Figure 5: ChIP versus CUT&Tag versus Single-Cell CUT&Tag Workflow Comparison
Side-by-side schematic of three epigenetic profiling methods illustrating input requirements, crosslinking necessity, resolution differences, and throughput capacity.
IP-MS: From Complex Identification to Quantitative Systems Biology
Immunoprecipitation coupled with mass spectrometry (IP-MS) generates protein interaction datasets that range from simple lists of co-purifying proteins to quantitative interaction dynamics across experimental conditions. The experimental design decisions that determine which level of information is obtained are made before the MS analysis begins.
Quantitative Strategies for IP-MS
Three quantification strategies dominate IP-MS. Label-free quantification (LFQ) compares spectral counts or precursor ion intensities between IP and control samples without isotopic labeling. LFQ is the simplest and most cost-effective approach, suitable for screening experiments where the goal is identifying high-confidence interactors, but its quantitative precision is limited by run-to-run LC-MS variability, typically achieving coefficients of variation of 20-30% for triplicate measurements. Stable isotope labeling by amino acids in cell culture (SILAC) incorporates heavy isotope-labeled amino acids (13C6-lysine, 13C6-arginine) into the proteome during cell culture, enabling multiplexed comparison of IP samples from different conditions in a single MS run. SILAC achieves CVs below 10% but requires metabolic labeling, limiting its use to cultured cells and excluding tissue samples. Tandem mass tag (TMT) labeling uses isobaric chemical tags to multiplex up to 18 samples in a single MS run, with the trade-off of reduced peptide identification depth due to ratio compression. For most IP-MS studies, the practical recommendation is LFQ for initial discovery and triage (comparing target IP vs control in triplicate), followed by SILAC or TMT validation of selected hits across multiple experimental conditions. A 2025 review in Current Opinion in Chemical Biology highlighted native MS as an emerging orthogonal approach that analyzes intact protein complexes without digestion, preserving stoichiometric information that is lost in conventional bottom-up IP-MS. The integration of native MS with IP enrichment is still primarily a specialized application but is becoming more accessible as commercial native MS platforms improve their sensitivity.
Data Quality Control and False Discovery Management
The CRAPome database (Contaminant Repository for Affinity Purification) is the standard reference for identifying common IP-MS contaminants. It aggregates negative control IP-MS experiments from over 700 datasets, providing frequency-of-detection scores for each protein. A protein that appears in more than 50% of CRAPome experiments should be treated as a likely contaminant unless it shows strong and reproducible enrichment in the target IP compared to the matched control. The SAINT (Significance Analysis of INTeractome) algorithm integrates spectral counts from target and control IPs, assigning a probability score to each candidate interactor. A SAINT score above 0.95 combined with a fold-change above 3 relative to control provides a recommended threshold for high-confidence interactors. Biological triplicates are essential for assessing reproducibility: proteins detected in at least two of three replicate IP-MS experiments with consistent spectral counts are substantially more likely to represent genuine interactions than those appearing in a single replicate. SILAC-based CoIP-MS services routinely incorporate SAINT scoring and CRAPome filtering in their data analysis pipeline to ensure that reported interactors meet these confidence thresholds.
Figure 6: IP-MS Quantitative Strategy Decision Tree
Decision logic guiding selection among label-free, SILAC, and TMT quantification based on sample type, multiplexing requirements, and quantitative precision needs.
Common Pitfalls, Artifacts, and Quality Control
The most reproducible errors in IP experiments are not random but stem from systematically underappreciated sources that affect every step of the workflow.
Antibody batch variation is the single largest uncontrolled variable in IP experiments. A 2024 survey of 30 commercial antibodies purchased in two different lot numbers found that 23% showed greater than 3-fold differences in IP yield between lots, and 10% lost all IP activity in the newer lot without any change in Western blot performance. The solution is to request a lot-specific validation report from the manufacturer before purchasing a new lot, and to reserve sufficient antibody from a validated lot to complete an entire study without lot changes.
Nonspecific binding to the bead matrix arises from three distinct mechanisms: (1) proteins with intrinsic affinity for agarose or sepharose polysaccharide matrices, particularly lectins and carbohydrate-binding proteins; (2) proteins that bind to the protein A or protein G ligand itself, independently of the antibody; and (3) proteins that aggregate or precipitate during the incubation and become trapped in the bead bed. These three sources can be distinguished by including beads-only and beads-plus-IgG controls in every experiment. Magnetic beads consistently show lower nonspecific binding than agarose beads across all three categories, with a 2- to 4-fold reduction in total background spectral counts in IP-MS experiments.
IgG contamination from the capture antibody itself is a well-known but incompletely solved problem. The IgG heavy chain at 50 kDa and light chain at 25 kDa dominate the mass range where many smaller-molecular-weight interactors are detected. On-bead digestion, in which the captured proteins are digested directly on the washed beads without eluting the antibody-antigen complex, substantially reduces IgG peptides compared to elution-based protocols because the intact antibody remains bound to protein A/G and is not released into the digestion solution. Crosslinking the antibody to protein A/G beads with DSS or BS3 before performing the IP allows denaturing elution conditions (SDS, urea, low pH) without co-eluting the antibody itself, eliminating IgG contamination entirely. This crosslinked-antibody approach is particularly recommended for IP-MS experiments targeting low-molecular-weight interactors below 50 kDa.
False positives from abundant background proteins—keratins from skin and hair, heat shock proteins that bind exposed hydrophobic surfaces, ribosomal proteins that are highly abundant and sticky—appear in virtually every IP-MS experiment regardless of the target. The CRAPome database is the primary tool for identifying these, but their presence should also be explicitly documented in the methods section of any publication reporting IP-MS results. A simple and effective reporting standard is to state that "keratins, heat shock proteins, and ribosomal proteins were identified in both target and control IPs and were excluded from further analysis unless they showed greater than 5-fold enrichment in the target IP."
Emerging Trends and Future Directions
Three developments are likely to reshape the IP landscape over the next 3-5 years.
AI-designed antibodies for IP. The demonstration by the David Baker laboratory in 2026 that machine learning can design antibodies with predetermined epitope specificity and optimized biophysical properties opens the possibility of generating IP-grade antibodies on demand, without animal immunization or hybridoma screening. If these computationally designed antibodies achieve the batch-to-batch consistency and affinity of recombinant antibodies at comparable cost, the current bottleneck of antibody validation for IP would be substantially reduced.
Automated IP platforms. Robotic liquid handlers adapted for magnetic bead-based IP can process 96 samples in parallel with a hands-on time of approximately 30 minutes, compared to 4-6 hours for manual processing of the same number of samples. Early adopters have demonstrated that automated IP achieves lower variability (CV 15% vs 35% for manual) and higher throughput, making population-scale interactomics studies feasible for the first time.
Integration with spatial and single-cell omics. The convergence of IP-based protein capture with spatial transcriptomics and single-cell proteomics technologies is creating multi-modal datasets that correlate protein interaction networks with gene expression at cellular resolution. A 2025 study combined IP-MS with spatial transcriptomics on adjacent tissue sections to map how protein interaction landscapes change across tumor microenvironments, identifying interactions that were spatially correlated with immune infiltration or drug resistance markers.
Figure 7: IP Technology Roadmap 2025-2030: From Manual Capture to AI-Driven Interactomics
Projected development timeline for AI antibody design, automated IP platforms, multi-omics integration, and real-time interaction monitoring technologies.
FAQ
- How do I validate whether my antibody is suitable for IP? Three tests are required: Western blot confirmation of target recognition at correct molecular weight, IP-WB showing target capture from lysate, and IP-MS comparison between wild-type and knockout samples to quantify target-to-background enrichment.
- What is the difference between standard IP and proximity labeling? Standard IP captures the target protein and its direct binding partners from cell lysate. Proximity labeling enzymatically tags all proteins within a defined spatial radius (approximately 10 nm for TurboID) in living cells, capturing both direct interactors and proteins that are physically close without direct contact.
- When should I use chemical crosslinking before IP? Use crosslinking when studying transient, low-affinity, or detergent-sensitive interactions that do not survive standard IP conditions. Chemical crosslinkers such as DSP or formaldehyde stabilize these labile interactions before lysis.
- How do I choose between TurboID and APEX2 for proximity labeling? TurboID labels within 10 minutes and has an effective labeling radius of approximately 10 nm, making it suitable for rapid dynamics. APEX2 labels within 1 minute but has a larger radius of approximately 20 nm, increasing bystander labeling.
- What is the advantage of CUT&Tag over traditional ChIP-seq? CUT&Tag requires 10,000-fold less input material (100-1,000 cells), eliminates sonication and crosslinking artifacts, achieves higher resolution at the antibody binding site, and produces lower background.
- How do I reduce nonspecific binding in IP-MS experiments? Use magnetic beads over agarose (2-4 fold reduction in background), implement on-bead digestion to reduce IgG contamination, and crosslink the antibody to the beads to allow denaturing washes.
References
- May DG, Scott KL, Campos AR, Roux KJ. Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation. Cells. 2020;9(5):1070. doi:10.3390/cells9051070
- Shin S, Lee SY, Kang MG, et al. Super-resolution proximity labeling with enhanced direct identification of biotinylation sites. Commun Biol. 2024;7:554. doi:10.1038/s42003-024-06112-w
- Liu F, Wu Z, Lv Z, et al. Cell fixation improves performance of in situ crosslinking mass spectrometry. Nat Commun. 2024;15:8595. doi:10.1038/s41467-024-52844-y
- Sarnowski C, Soderblom E, Madden D, et al. TurboID-mediated proximity labeling for virus-host interaction identification. Front Cell Infect Microbiol. 2024;14:1371837. doi:10.3389/fcimb.2024.1371837
- Khaligh SS, Khalid-Salako F, Kurt H, Yuce M. Exploring the Interaction of Biotinylated FcGamma RI and IgG1 Monoclonal Antibodies on Streptavidin-Coated Plasmonic Sensor Chips for Label-Free VEGF Detection. Biosensors. 2024;14(12):634. doi:10.3390/bios14120634
